Boaz P Levi
Associate Investigator
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (25)
Year:
2026
The mammalian basal ganglia (BG) orchestrate motor, cognitive, and affective functions, yet cell type-specific genetic access remains limited, especially beyond rodents. Key structures implicated in movement and psychiatric disorders, including pallidum, subthalamic nucleus, and dopaminergic midbrain, lack scalable tools for cross-species targeting. Here, we present a comprehensive enhancer-AAV library enabling selective labeling and manipulation of major BG neuronal populations: striatal projection neuron subtypes, pallidal and subthalamic neurons, and midbrain dopaminergic and GABAergic populations. Using an evolutionarily informed discovery pipeline, we identified enhancers targeting canonical, non-canonical, and disease-relevant cell types, with validation demonstrating robust cross-species conservation of specificity between mouse and macaque. Computational modeling revealed sequence features predictive of in vivo performance, including motif grammar, chromatin accessibility, and evolutionary conservation, and identified distinct regulatory architectures across glial, projection, and interneuron lineages. This work establishes the first comprehensive cross-species viral toolkit for the BG, unlocking previously inaccessible cell types for circuit dissection.
Year:
2026
Profound degeneration of dopamine (DA) neurons and reduced DA levels in the brain is recognized as an underlying cause of Parkinson’s Disease (PD). The standard treatment for PD is levodopa (L-DOPA), but its effectiveness wanes over time and prolonged usage can lead to L-DOPA-induced-dyskinesia (LID). An adeno-associated virus (AAV)-based strategy to overexpress aromatic l-amino acid decarboxylase (AADC) in the striatum combined with LDOPA therapy shows promise for symptomatic improvement but requires an invasive delivery approach. Here, we generated enhancer AAVs to drive AADC expression in key cell types and paired them with a blood-brain barrier (BBB)-penetrant capsid. We characterized the AAVs in mouse following multiple routes of administration and found that cell-type specific viral treatment ameliorated motor deficits and LID in PD disease models. This cell type-specific viral rescue strategy showed similar or better phenotypic rescue compared to a ubiquitous targeting approach and improved mortality. Additionally, we characterized the expression of an AAVAADC vector capable of mouse phenotypic rescue in non-human primate (NHP) following two routes of administration. This novel therapeutic strategy in combination with L-DOPA may enable a less invasive and better tolerated approach to treat motor deficits in PD patients.
Year:
2026
Profound degeneration of dopamine (DA) neurons and reduced DA levels in the brain is recognized as an underlying cause of Parkinson’s Disease (PD). The standard treatment for PD is levodopa (L-DOPA), but its effectiveness wanes over time and prolonged usage can lead to L-DOPA-induced-dyskinesia (LID). An adeno-associated virus (AAV)-based strategy to overexpress aromatic l-amino acid decarboxylase (AADC) in the striatum combined with L-DOPA therapy shows promise for symptomatic improvement but requires an invasive delivery approach. Here, we generated enhancer AAVs to drive AADC expression in key cell types and paired them with a blood-brain barrier (BBB)-penetrant capsid. We characterized the AAVs in mouse following multiple routes of administration and found that cell-type specific viral treatment ameliorated motor deficits and LID in PD disease models. This cell type-specific viral rescue strategy showed similar or better phenotypic rescue compared to a ubiquitous targeting approach and improved mortality. Additionally, we characterized the expression of an AAV-AADC vector capable of mouse phenotypic rescue in non-human primate (NHP) following two routes of administration. This novel therapeutic strategy in combination with L-DOPA may enable a less invasive and better tolerated approach to treat motor deficits in PD patients.
Year:
2026
Year:
2025
Astrocytes shape synapses and circuits, yet human basal ganglia astrocyte diversity is incompletely defined. We built a multimodal atlas by integrating single-nucleus RNA-sequencing and chromatin accessibility with DNA methylation, 3D chromatin conformation, and spatial transcriptomics, then mapped basal ganglia programs onto a whole-brain reference. Astrocytes segregated into three anatomical subgroups spanning striatal gray matter, extra-striatal gray matter, and white matter, with subgroup-biased neurotransmitter transporters and synapse-associated programs consistent with differences in dominant afferent input. Within striatum, dorsal and ventral astrocyte populations aligned with distinct microcircuits and were conserved in nonhuman primates. A deep learning sequence model identified subgroup-associated enhancer code and, when benchmarked against published enhancer-AAV datasets, supported the design of candidate viral tools to target basal ganglia astrocyte programs in vivo . Together, these data define major axes of human astrocyte specialization and provide a framework for cell type-specific dissection of basal ganglia function.
Year:
2025
The basal ganglia (BG) are conserved brain regions essential for motor control, learning, emotion, and cognition, and are implicated in neurological and psychiatric disease. Yet a unified cross-species taxonomy of BG cell types is lacking, limiting translation of BG circuit mechanisms, interpretation of human genetic risk, and development of cell type-targeted tools. We present a multiomic consensus atlas of 1.8 million nuclei from human, macaque, and marmoset spanning eight BG structures. Integrating cross-species gene expression, open chromatin, and spatial profiling enables definition of conserved and divergent cell types. Alignment to existing mouse and human atlases identifies 61 homologous cell types conserved over 80 million years. We identify a STRd D2 StrioMat Hybrid medium spiny neuron (MSN) type with molecular, electrophysiological, and morphological features that clarify hybrid MSN identities. Comparative cis-regulatory analysis reveals conserved sequence grammars that encode cell identity and inform viral targeting strategies, providing a foundational resource for BG evolution, function, and disease.
Year:
2025
Proper brain function requires the assembly and function of diverse populations of neurons and glia. Single cell gene expression studies have mostly focused on characterization of neuronal cell diversity; however, recent studies have also revealed substantial diversity of glial cells, particularly astrocytes. To better understand glial cell types and their roles in neurobiology, we built a new suite of adeno-associated viral (AAV)-based genetic tools to enable genetic access to astrocytes and oligodendrocytes. These oligodendrocyte and astrocyte enhancer-AAVs are highly specific (usually > 95% cell type specificity) with variable expression levels, and the astrocyte enhancer-AAVs show multiple distinct expression patterns reflecting the spatial distribution of astrocyte cell types. To provide the best glial-specific functional tools, several enhancer-AAVs were: optimized for higher expression levels, shown to be functional and specific in rat and macaque, shown to maintain specific activity across transgenes and in epilepsy where traditional promoters changed activity, and used to drive functional transgenes in astrocytes including Cre recombinase and acetylcholine-responsive sensor iAChSnFR. The astrocyte-specific iAChSnFR revealed a clear reward-dependent acetylcholine response in astrocytes of the nucleus accumbens during reinforcement learning. Together, this collection of glial enhancer-AAVs will enable characterization of astrocyte and oligodendrocyte populations and their roles across species, disease states, and behavioral epochs.
Year:
2025
Proper brain function requires the assembly and function of diverse populations of neurons and glia. Single cell gene expression studies have mostly focused on characterization of neuronal cell diversity; however, recent studies have also revealed substantial diversity of glial cells, particularly astrocytes. To better understand glial cell types and their roles in neurobiology, we built a new suite of adeno-associated viral (AAV)-based genetic tools to enable genetic access to astrocytes and oligodendrocytes. These oligodendrocyte and astrocyte enhancer-AAVs are highly specific (usually > 95% cell type specificity) with variable expression levels, and the astrocyte enhancer-AAVs show multiple distinct expression patterns reflecting the spatial distribution of astrocyte cell types. To provide the best glial-specific functional tools, several enhancer-AAVs were: optimized for higher expression levels, shown to be functional and specific in rat and macaque, shown to maintain specific activity across transgenes and in epilepsy where traditional promoters changed activity, and used to drive functional transgenes in astrocytes including Cre recombinase and acetylcholine-responsive sensor iAChSnFR. The astrocyte-specific iAChSnFR revealed a clear reward-dependent acetylcholine response in astrocytes of the nucleus accumbens during reinforcement learning. Together, this collection of glial enhancer-AAVs will enable characterization of astrocyte and oligodendrocyte populations and their roles across species, disease states, and behavioral epochs.
Year:
2025
Adeno-associated virus (AAV) vectors are pivotal in gene therapy for neurological disorders due to their ability to enable long-term gene expression in the central nervous system (CNS). However, transducing larger brains, such as those of non-human primates (NHPs), remains challenging, necessitating alternative delivery routes and optimized capsids. This study directly compares the transduction efficiency and biodistribution of the benchmark AAV9 and its engineered derivative, AAV-PHP.eB, following intracerebroventricular (ICV) administration in juvenile Macaca nemestrina . Employing a neuron-specific promoter and nuclear-localized reporter, we systematically quantified transduction across cortical, subcortical, and spinal regions. AAV-PHP.eB demonstrated significantly higher transduction rates in cortical and spinal regions compared to AAV9, despite similar expression patterns. Both vectors exhibited limited subcortical penetration and significant peripheral leakage, highlighting key challenges in CNS targeting. This is the first study to quantitatively compare AAV-PHP.eB and AAV9 in NHPs, providing valuable insights into the advantages and limitations of engineered AAV capsids for CNS gene therapy. These findings lay a critical foundation for optimizing vector designs and delivery strategies to improve outcomes in clinical applications for neurodegenerative and neurodevelopmental disorders.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (44)
Fenna Krienen
Assistant Professor
Princeton University
Nathan Zemke
Assistant Professor
University of California, San Diego
Trygve Bakken
Allen Institute for Brain Science
Kenta M Hagihara
Group Leader
生理学研究所/National Institute for Physiological Sciences
Rachel Dalley
Allen Institute for Brain Science
Natalia Goriounova
University of Amsterdam
Yang Li
Assistant Professor
Washington University in St. Louis
Richard Ellenbogen
Professor and Chairman
University of Washington
Gregory D. Horwitz
Professor
University of Washington
Han Hou
Scientist
Allen Institute for Brain Science
Joseph Ecker
Salk Institute for Biological Studies
Annika Keller
University Hospital of Zurich
Huib Mansvelder
University of Amsterdam
Kai Zhang
Assistant Professor
Westlake University
David Osumi-Sutherland
Wellcome Sanger Institute
Jennie Close
Senior Scientist
Allen Institute for Brain Science
Jesse Gillis
Associate Professor
University of Toronto
Hongkui Zeng
Executive Director
Allen Institute for Brain Science
Partha Mitra
Cold Spring Harbor Laboratory
Ruchi Lohia
University of Pennsylvania
Kaspar Podgorski
Senior Scientist
Allen Institute for Brain Science
Bosiljka Tasic
Director
Allen Institute for Brain Science
Jeroen Eggermont
Senior Researcher
Leiden University Medical Center
Christopher Keene
Professor and Chair
University of California, San Diego
Bing Ren
Professor
University of California, San Diego
Stein Aerts
Professor
KU Leuven
Boudewijn Lelieveldt
Delft University of Technology
Yoshiko Kojima
Research Associate Professor
University of Washington
Yoshiaki Tanaka
Associate Professor
Université de Montréal
Abhejit Rajagopal
Assistant Professor
University of California, San Francisco
Meng Zhang
Scripps Research Institute
Alex Hughes
Assistant Research Professor
University of Colorado Anschutz Medical Campus
Nick Goeden
Chief Science Officer
Asymptote Genetic Medicines
John Mich
Allen Institute
Brian Kalmbach
Allen Institute for Brain Science
Chelsea Pagan
Allen Institute
Min Jee Jang
Assistant Professor
University of Illinois at Urbana-Champaign
Brian Long
Allen Institute for Brain Science
Jay Shendure
Professor
University of Washington
Scott Owen
Assistant Professor
Stanford University School of Medicine
Michael Kunst
Senior Scientist
Allen Institute for Brain Science
Jean-Benoît Lalanne
Assistant professor
Université de Montréal
Svoboda Karel
Director
Allen Institute for Brain Science
Herman Tung
Allen Institute
Make your next move.
Prepare your application
Review drafts before you send them.